Literature DB >> 30976586

Periocular Histiocytoid Carcinoma: Potential Diagnostic Challenges.

Joseph R Yates1, Michael J Mines2, Prem S Subramanian3, Roxana Rivera-Michlig4, Thomas J Cummings5, Charles G Eberhart1,4.   

Abstract

Cutaneous histiocytoid carcinoma can occur as a primary tumor of the periocular region. Morphologically similar histiocytoid carcinomas arising as primary tumors of the breast have a predilection for orbital metastases. They can occasionally contain regions with prominent vacuolated cytoplasm and minimal nuclear atypia, which mimic benign histiocytic lesions. Differentiating nonneoplastic, primary neoplastic, and metastatic histiocytoid lesions involving the periorbita can be challenging for both the clinician and the pathologist, and this distinction has management implications. Herein, we present 3 cases to illustrate the challenges of diagnosing periocular histiocytoid carcinoma.

Entities:  

Keywords:  Eyelid; Histiocytoid carcinoma; Metastasis; Orbit; Signet-ring cell carcinoma

Year:  2018        PMID: 30976586      PMCID: PMC6422134          DOI: 10.1159/000490250

Source DB:  PubMed          Journal:  Ocul Oncol Pathol        ISSN: 2296-4657


  3 in total

1.  Sclerosing Signet Ring Cell Carcinoma of the Lacrimal Gland: A Potentially New Primary Entity.

Authors:  Frederick A Jakobiec; Edith R Reshef; Lina Ma; Martin K Selig; Daniel R Lefebvre; Anna M Stagner
Journal:  Ocul Oncol Pathol       Date:  2020-02-07

2.  Genetic Panel Test of Double Cancer of Signet-Ring Cell/Histiocytoid Carcinoma of the Eyelid and Papillary Thyroid Carcinoma: Case Report and Literature Review.

Authors:  Masashi Kuroki; Hirofumi Shibata; Bunya Kuze; Toshimitsu Ohashi; Keishi Kohyama; Hisakazu Kato; Hiroki Kato; Tatsuhiko Miyazaki; Hiroyuki Tomita; Takenori Ogawa
Journal:  Cureus       Date:  2022-05-21

Review 3.  Current Diagnosis and Treatment Options for Cutaneous Adnexal Neoplasms with Apocrine and Eccrine Differentiation.

Authors:  Iga Płachta; Marcin Kleibert; Anna M Czarnecka; Mateusz Spałek; Anna Szumera-Ciećkiewicz; Piotr Rutkowski
Journal:  Int J Mol Sci       Date:  2021-05-11       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.